Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP28 | Q96RU2 | 1/20 | 0.52 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CCR5 | P51681 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12293723 | 1.00 | USP28 (0.52) | USP28USP25HTTALDH1A1CCR5 | |
| SCHEMBL9287833 | 0.88 | HTT (0.46) | USP28USP25HTTALDH1A1CCR5 | |
| SCHEMBL15150708 | 0.87 | CCR5 (0.47) | USP28USP25HTTALDH1A1CCR5 | |
| SCHEMBL27530657 | 0.87 | CCR5 (0.47) | USP28USP25HTTALDH1A1CCR5 | |
| SCHEMBL15148414 | 0.85 | CCR5 (0.53) | USP28USP25HTTALDH1A1CCR5 | |
| SCHEMBL724632 | 0.85 | CCR5 (0.53) | USP28USP25HTTALDH1A1CCR5 | |
| SCHEMBL12403881 | 0.85 | CCR5 (0.48) | USP28USP25HTTALDH1A1CCR5 | |
| SCHEMBL4064320 | 0.84 | PTGER1 (0.44) | USP28USP25ALDH1A1LMNASLC6A4 | |
| SCHEMBL12121777 | 0.84 | PTGER1 (0.44) | USP28USP25ALDH1A1LMNASLC6A4 | |
| SCHEMBL12856629 | 0.84 | CFD (0.39) | USP28USP25HTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | claimed |
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2013-08-01 | — | — | US | claimed |
| WO-2012098560-A2 | PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST | MSN LABORATORIES LIMITED (IN) | 2012-07-26 | — | — | WO | claimed |
| WO-2012025941-A2 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2012-03-01 | — | — | WO | claimed |
| EP-2855421-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES | CRYSTAL PHARMA SAU (ES) | 2018-03-21 | — | — | EP | disclosed |
| US-9422228-B2 | Process for the preparation of optically pure fesoterodine derivatives | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-23 | — | — | US | disclosed |
| US-9422228-B2 | Process for the preparation of optically pure fesoterodine derivatives | CRYSTAL PHARMA, S.A.U. (ES) | 2016-08-23 | — | — | US | disclosed |
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-20150094485-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES | CURIA SPAIN, S.A.U. (ES) | 2015-04-02 | — | — | US | disclosed |
| US-20150094485-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES | CURIA SPAIN, S.A.U. (ES) | 2015-04-02 | — | — | US | disclosed |
| EP-0957073-A1 | Novel derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 1999-11-17 | — | — | EP | disclosed |
| WO-1998043942-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-10-08 | — | — | WO | disclosed |
| EP-0667852-B1 | NOVEL 3,3-DIPHENYLPROPYLAMINES, THEIR USE AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-04-08 | — | — | EP | disclosed |
| US-5686464-A | ANTICHOLINERGIC AGENTS; URINARY INCONTINENCE TREATMENT | PHARMACIA AB (SE) | 1997-11-11 | — | — | US | disclosed |
| US-5559269-A | ANTICHOLINERGIC AGENTS | PHARMACIA AB (SE) | 1996-09-24 | — | — | US | disclosed |
| EP-0667852-A1 | NOVEL 3,3-DIPHENYLPROPYLAMINES, THEIR USE AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994011337-A9 | NOVEL 3,3-DIPHENYLPROPYLAMINES, THEIR USE AND PREPARATION | — | 1995-07-06 | — | — | WO | disclosed |
| WO-1994011337-A1 | NOVEL 3,3-DIPHENYLPROPYLAMINES, THEIR USE AND PREPARATION | PHARMACIA AB (SE) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | QDPR, FES, SULT1A1 | USP28 2048/4885USP25 1260/4885HTT 1119/4885 |
| US-20150094485-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES | ADH1C, NISCH, ADH1A | USP28 3945/4885USP25 3957/4885HTT 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.